The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
نویسندگان
چکیده
Nicolle H. Rekers *, Veronica Olivo Pimentel*, Ala Yaromina, Natasja G. Lieuwes, Rianne Biemans, Catharina M. L. Zegers, Wilfred T. V. Germeraad, Evert J. Van Limbergen, Dario Neri, Ludwig J. Dubois **, and Philippe Lambin** Department of Radiotherapy, The M-Lab group, GROW School for Oncology and Developmental Biology, Maastricht Comprehensive Cancer Centre, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Division of Hematology, GROW – School for Oncology and Developmental Biology, Maastricht Comprehensive Cancer Centre, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Z€urich, Switzerland; Department of Radiotherapy, The D-Lab, GROW School for Oncology and Developmental Biology, Maastricht Comprehensive Cancer Center, Maastricht University Medical Center, Maastricht, The Netherlands
منابع مشابه
Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
Recently, we have shown that radiotherapy (RT) combined with L19-IL2 can induce a long-lasting antitumor effect, dependent on ED-B expression and infiltration of cytotoxic T cells. These findings will be translated to a Phase I clinical study (NCT02086721) in patients with oligometastatic solid tumors. See this link for the animation: http://youtu.be/xHbwQuCTkRc.
متن کاملRadiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
PURPOSE Radiotherapy modifies the tumor microenvironment and causes the release of tumor antigens, which can enhance the effect of immunotherapy. L19 targets the extra domain B (ED-B) of fibronectin, a marker for tumor neoangiogenesis, and can be used as immunocytokine when coupled to IL2. We hypothesize that radiotherapy in combination with L19-IL2 provides an enhanced antitumor effect, which ...
متن کاملCancer Therapy: Preclinical RadiotherapyCombinedwith the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Purpose: Radiotherapy modifies the tumor microenvironment and causes the release of tumor antigens, which can enhance the effect of immunotherapy. L19 targets the extra domain B (ED-B) of fibronectin, a marker for tumor neoangiogenesis, and can be used as immunocytokine when coupled to IL2. We hypothesize that radiotherapy in combination with L19-IL2 provides an enhanced antitumor effect, which...
متن کاملComplete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2.
The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anticancer therapy, but is largely unexplored in hematologic malignancies. In the present study, we show that the extra domain B (EDB) of fibronectin, a marker of angiogenesis, is expressed in B-cell non-Hodgkin lymphoma (NHL) and that the human monoclonal anti-EDB antibody L19 can select...
متن کاملThe targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
PURPOSE Effective control of pancreatic cancer has been hampered primarily by the lack of tumor specificity of current treatment modalities. The highly specific antibody-mediated delivery of therapeutic agents to the tumor microenvironment might overcome this problem. We therefore investigated the therapeutic efficacy of the targeted immunocytokine L19-Interleukin-2 (L19-IL2), consisting of the...
متن کامل